Indivior Plc (INDV)

$32.97 -0.57 (-1.70%)
Market Cap 4.19B
Revenue (ttm) 1.19B
Net Income (ttm) 2.00M
EPS (ttm) N/A
PE Ratio 16.83
Forward PE 11.40
Profit Margin 0.17%
Debt to Equity Ratio -1.56
Volume 1,112,500
Avg Vol 2,478,264
Day's Range N/A - N/A
Shares Out 125.02M
Stochastic %K 28%
Beta 0.75
Analysts Strong Sell
Price Target $46.40

Company Profile

Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE T...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 804 379 1090
Address:
10710 Midlothian Turnpike, Suite 125, North Chesterfield, United States
ExtinctionBurst
ExtinctionBurst Feb. 22 at 4:28 AM
$ATER Despite financial struggles, the company has expanded its sales channels, recently launching products on BedBathandBeyond.com and HomeDepot.com, and introducing a new "Tallow Skin Care" line under its Healing Solutions brand. $INDV .Indivior is scheduled to report its Q4 and Full-Year 2025 financial results on Thursday, February 26, 2026, before the market opens. $KYNB Upcoming Investor Presentations: Management is scheduled to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the Leerink Global Healthcare Conference on March 11
1 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 4:22 PM
$INDV Q4: Growth story or margin squeeze? 👀 Sublocade growth is in focus, but Suboxone pressure and the 2026 revenue outlook are just as critical. This quarter isn’t just about numbers — it’s about whether the long-term trajectory still holds. Want the full breakdown before earnings hit? Discover what’s in the cards 👉 https://www.zacks.com/stock/news/2872113/indivior-pharmaceuticals-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872113-teaser-34240&ADID=SYND_STOCKTWITS_TWEET_2_2872113_TEASER_34240
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 3:22 PM
$INDV saw a 282.2% rise over the past year—can it keep soaring post-earnings? 🚀 📈 Sublocade's double-digit growth 📉 Suboxone hit by generic competition 🧪 Key pipeline updates expected Find out if the rally can continue 👉 https://www.zacks.com/stock/news/2872113/indivior-pharmaceuticals-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872113-body-34235&ADID=SYND_STOCKTWITS_TWEET_2_2872113_BODY_34235
0 · Reply
LarryCoakley944
LarryCoakley944 Feb. 18 at 1:48 PM
$INDV Specialty pharma with opioid treatment exposure.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 24 at 3:49 AM
$INDV Current Stock Price: $32.96 Contracts to trade: $35 INDV Feb 20 2026 Call Entry: $0.50 Exit: $0.76 ROI: 52% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
gratitude11
gratitude11 Jan. 22 at 3:36 PM
$INDV started a position here at $33.70
1 · Reply
Brockenspectre
Brockenspectre Dec. 26 at 2:37 PM
$INDV Conditions are shifting toward markets rewarding operational proof over narrative ambition. Capital allocation choices will reveal true priorities. Demonstrated durability would lengthen investor time horizons. Sentiment should follow consistency rather than noise.
0 · Reply
TalkMarkets
TalkMarkets Dec. 24 at 9:14 AM
Supply Absorbed: Watch This Accumulation Pattern Play Out $SPX $INDV $KGC $OKLO https://talkmarkets.com/content/stocks--equities/supply-absorbed-watch-this-accumulation-pattern-play-out?post=546531&userid=166882
0 · Reply
howardlindzon
howardlindzon Dec. 16 at 12:15 AM
$INDV now that fentanyl is. war crime I guess we can start dropping them on venezuela - which should be good for sales
0 · Reply
BDipNRip
BDipNRip Dec. 15 at 10:19 PM
$INDV WeN58? Need to fly home!
0 · Reply
Latest News on INDV
Indivior to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 33 minutes ago

Indivior to Participate in Upcoming Investor Conferences

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26áµ—Ê°

Jan 28, 2026, 7:00 AM EST - 27 days ago

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26áµ—Ê°

Indivior Announces Completion of Redomiciliation to the United States

Jan 26, 2026, 7:00 AM EST - 4 weeks ago

Indivior Announces Completion of Redomiciliation to the United States

Indivior Provides Full-Year 2026 Financial Guidance and Business Update

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Indivior Provides Full-Year 2026 Financial Guidance and Business Update

Indivior Announces Inclusion in the S&P SmallCap 600® Index

Dec 22, 2025, 7:00 AM EST - 2 months ago

Indivior Announces Inclusion in the S&P SmallCap 600® Index

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

Dec 17, 2025, 11:30 AM EST - 2 months ago

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

Indivior Concludes Legacy U.S. Department of Justice Matter

Nov 20, 2025, 4:01 PM EST - 3 months ago

Indivior Concludes Legacy U.S. Department of Justice Matter

Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 9:21 AM EST - 3 months ago

Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

Nov 3, 2025, 8:00 AM EST - 4 months ago

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

Indivior PLC (INDV) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:56 PM EDT - 4 months ago

Indivior PLC (INDV) Q3 2025 Earnings Call Transcript

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

Indivior to Participate in the Stifel 2025 Healthcare Conference

Oct 28, 2025, 10:00 AM EDT - 4 months ago

Indivior to Participate in the Stifel 2025 Healthcare Conference

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

Oct 16, 2025, 4:04 PM EDT - 4 months ago

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

Oct 15, 2025, 8:00 AM EDT - 4 months ago

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

UK's Indivior to re-domicile to US after listing move

Oct 1, 2025, 9:35 AM EDT - 5 months ago

UK's Indivior to re-domicile to US after listing move

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Oct 1, 2025, 8:00 AM EDT - 5 months ago

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 11:44 AM EDT - 6 months ago

Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Indivior to Participate in Upcoming Investor Events

Aug 20, 2025, 12:00 PM EDT - 6 months ago

Indivior to Participate in Upcoming Investor Events

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Aug 5, 2025, 5:39 PM EDT - 7 months ago

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 5:22 AM EDT - 7 months ago

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Jul 31, 2025, 7:00 AM EDT - 7 months ago

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jul 25, 2025, 2:00 AM EDT - 7 months ago

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Jul 23, 2025, 8:00 AM EDT - 7 months ago

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Jul 17, 2025, 9:00 AM EDT - 7 months ago

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Jul 8, 2025, 8:00 AM EDT - 8 months ago

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Jun 30, 2025, 7:00 AM EDT - 8 months ago

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Indivior Appoints Tony Kingsley to the Board of Directors

Jun 24, 2025, 4:12 PM EDT - 8 months ago

Indivior Appoints Tony Kingsley to the Board of Directors

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Jun 19, 2025, 9:00 AM EDT - 8 months ago

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Jun 2, 2025, 2:33 AM EDT - 9 months ago

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jun 2, 2025, 2:00 AM EDT - 9 months ago

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Announces Patrick Barry as Chief Commercial Officer

May 27, 2025, 8:30 AM EDT - 9 months ago

Indivior Announces Patrick Barry as Chief Commercial Officer

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

May 1, 2025, 10:27 AM EDT - 10 months ago

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

Indivior: Trying To Break Addiction

Apr 28, 2025, 12:12 PM EDT - 10 months ago

Indivior: Trying To Break Addiction

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Apr 24, 2025, 10:45 AM EDT - 10 months ago

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Indivior Announces Q1 2025 Financial Results

Apr 24, 2025, 2:00 AM EDT - 10 months ago

Indivior Announces Q1 2025 Financial Results

Indivior Announces Further Changes to Board of Directors

Mar 4, 2025, 8:40 AM EST - 1 year ago

Indivior Announces Further Changes to Board of Directors

UK's Indivior appoints Joe Ciaffoni as CEO

Feb 27, 2025, 2:48 AM EST - 1 year ago

UK's Indivior appoints Joe Ciaffoni as CEO

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Feb 27, 2025, 2:00 AM EST - 1 year ago

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Feb 24, 2025, 2:00 AM EST - 1 year ago

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:26 PM EST - 1 year ago

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Feb 20, 2025, 2:13 PM EST - 1 year ago

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

UK's Indivior forecasts 17% decline in 2025 revenue

Feb 20, 2025, 2:55 AM EST - 1 year ago

UK's Indivior forecasts 17% decline in 2025 revenue

Indivior Announces FY and Q4 2024 Financial Results

Feb 20, 2025, 2:00 AM EST - 1 year ago

Indivior Announces FY and Q4 2024 Financial Results

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Feb 12, 2025, 2:00 AM EST - 1 year ago

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Nov 19, 2024, 12:52 PM EST - 1 year ago

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Nov 7, 2024, 2:24 PM EST - 1 year ago

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Oct 30, 2024, 12:30 PM EDT - 1 year ago

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 2:02 PM EDT - 1 year ago

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Indivior Announces Q3 2024 Financial Results

Oct 24, 2024, 2:00 AM EDT - 1 year ago

Indivior Announces Q3 2024 Financial Results

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Oct 13, 2024, 10:00 AM EDT - 1 year ago

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

ExtinctionBurst
ExtinctionBurst Feb. 22 at 4:28 AM
$ATER Despite financial struggles, the company has expanded its sales channels, recently launching products on BedBathandBeyond.com and HomeDepot.com, and introducing a new "Tallow Skin Care" line under its Healing Solutions brand. $INDV .Indivior is scheduled to report its Q4 and Full-Year 2025 financial results on Thursday, February 26, 2026, before the market opens. $KYNB Upcoming Investor Presentations: Management is scheduled to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the Leerink Global Healthcare Conference on March 11
1 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 4:22 PM
$INDV Q4: Growth story or margin squeeze? 👀 Sublocade growth is in focus, but Suboxone pressure and the 2026 revenue outlook are just as critical. This quarter isn’t just about numbers — it’s about whether the long-term trajectory still holds. Want the full breakdown before earnings hit? Discover what’s in the cards 👉 https://www.zacks.com/stock/news/2872113/indivior-pharmaceuticals-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872113-teaser-34240&ADID=SYND_STOCKTWITS_TWEET_2_2872113_TEASER_34240
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 3:22 PM
$INDV saw a 282.2% rise over the past year—can it keep soaring post-earnings? 🚀 📈 Sublocade's double-digit growth 📉 Suboxone hit by generic competition 🧪 Key pipeline updates expected Find out if the rally can continue 👉 https://www.zacks.com/stock/news/2872113/indivior-pharmaceuticals-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872113-body-34235&ADID=SYND_STOCKTWITS_TWEET_2_2872113_BODY_34235
0 · Reply
LarryCoakley944
LarryCoakley944 Feb. 18 at 1:48 PM
$INDV Specialty pharma with opioid treatment exposure.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 24 at 3:49 AM
$INDV Current Stock Price: $32.96 Contracts to trade: $35 INDV Feb 20 2026 Call Entry: $0.50 Exit: $0.76 ROI: 52% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
gratitude11
gratitude11 Jan. 22 at 3:36 PM
$INDV started a position here at $33.70
1 · Reply
Brockenspectre
Brockenspectre Dec. 26 at 2:37 PM
$INDV Conditions are shifting toward markets rewarding operational proof over narrative ambition. Capital allocation choices will reveal true priorities. Demonstrated durability would lengthen investor time horizons. Sentiment should follow consistency rather than noise.
0 · Reply
TalkMarkets
TalkMarkets Dec. 24 at 9:14 AM
Supply Absorbed: Watch This Accumulation Pattern Play Out $SPX $INDV $KGC $OKLO https://talkmarkets.com/content/stocks--equities/supply-absorbed-watch-this-accumulation-pattern-play-out?post=546531&userid=166882
0 · Reply
howardlindzon
howardlindzon Dec. 16 at 12:15 AM
$INDV now that fentanyl is. war crime I guess we can start dropping them on venezuela - which should be good for sales
0 · Reply
BDipNRip
BDipNRip Dec. 15 at 10:19 PM
$INDV WeN58? Need to fly home!
0 · Reply
AAUS1
AAUS1 Dec. 15 at 12:58 PM
$INDV $41 in few days ?
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 1:45 PM
$INDV Current Stock Price: $36.00 Contracts to trade: $35 INDV Dec 19 2025 Call Entry: $1.83 Exit: $2.58 ROI: 41% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
AAUS1
AAUS1 Dec. 9 at 4:00 PM
$INDV Superb consolidation at these levels promises good next few days !!
0 · Reply
AAUS1
AAUS1 Dec. 8 at 4:45 PM
$INDV $42 is given
0 · Reply
victorgn
victorgn Dec. 8 at 3:44 PM
$INDV Back to $39 .. huge Market
0 · Reply
WAJeff
WAJeff Dec. 8 at 3:06 PM
$INDV $38 ath
0 · Reply
howardlindzon
howardlindzon Dec. 8 at 1:43 PM
$INDV the opiode dependence drug just keeps going...sad but very america
1 · Reply
AstroFuel
AstroFuel Dec. 8 at 1:14 PM
$INDV $200
0 · Reply
AstroFuel
AstroFuel Dec. 5 at 6:02 PM
$INDV
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 25 at 6:15 PM
The XBI is up 73% since hitting its low on 4/8/2025. Attached is a list of the % change in share price for all commercial-stage bio (oncology & non-oncology) since their 4/8/25 close. SCOPE: Market caps over $100MM 11 of 35 commercial-stage oncology focused bios beat the XBI during this time. In non-oncology 35 of 90 have done so. FDA approval dates are provided if you want to exclude ​NUVB was not technically commercial-stage on 4/8/25 but its on our list. $ADCT & $RIGL were otherwise the top performing stocks in this peer group. $ARWR $INDV & $EYPT have been the best performing stocks in non-oncology. This is for entertainment purposes only. This is not investment advice
1 · Reply